Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ID: DRG0FDLHR)
| ADC Name |
37486969 ADC 36
|
|||||
|---|---|---|---|---|---|---|
| Synonyms |
ADC 36
Click to Show/Hide
|
|||||
| Organization |
Mersana Therapeutics, Inc.; 3-Dimensional Consulting.
|
|||||
| Drug Status |
Investigative
|
|||||
| Drug-to-Antibody Ratio |
8
|
|||||
| Antibody Name |
Trastuzumab
|
Antibody Info | ||||
| Antigen Name |
Receptor tyrosine-protein kinase erbB-2 (HER2)
|
Antigen Info | ||||
| Payload Name |
STING Agonist 6
|
Payload Info | ||||
| Linker Name |
Undisclosed
|
|||||
| Conjugate Type |
Site-specific bioconjugation at Trastuzumab-Lys248-thiol
|
|||||
2027 Update
General Information of The ADMET Data Related to This ADC
Absorption
| Standard Type | Value | Units | Description | Reference |
|---|---|---|---|---|
| Area Under the Concentration-Time Curve (AUC) | 499 | day·ng/mL |
In vivo mouse plasma PK analysis for the conjugated drug of ADC, AUCinf.
|
[1] |
Excretion
| Standard Type | Value | Units | Description | Reference |
|---|---|---|---|---|
| Clearance (CL) | 65.2 | mL/day/kg |
In vivo mouse plasma PK analysis for the conjugated drug of ADC.
|
[1] |
References